Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals

Antiviral Therapy

Volumn 14, Issue 7, 2009, Pages 1001-1004

  Van Der Lugt, Jasper ^a,b,c   Lange, Joep ^a,c   Avihingsanon, Anchalee ^a   Ananworanich, Jintanat ^a,d   Sealoo, Siriporn ^a   Burger, David ^e   Gorowara, Meena ^a   Phanuphak, Praphan ^a   Ruxrungtham, Kiat ^a,f  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b International Antiretroviral Trial Evaluation Centre   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d South East Asia Research Collaboration with Hawaii ^*  (Thailand)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUVIA; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG STABILITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; TABLET FORMULATION;

ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUGS, GENERIC; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; TABLETS;

EID: 72249097523     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1410     Document Type: Article

References (11)

1. Vasan A, Hoos D, Mukherjee JS, Farmer PE, Rosenfield AG, Perriens JH. The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund. Bull World Health Organ 2006; 84:393-398.
2. World Health Organization. The global price reporting mechanism. Geneva: World Health Organization 2006.
3. Chien CV. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare? PLoS One 2007; 2:e278.
4. World Health Organization, UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization 2008. (Accessed 20 October 2009.) Available from http://www.who.int/hiv/pub/towards-universal-access-report-2008.pdf
5. World Health Organization, UNAIDS. Report on WHO/ UNAIDS meeting on forecasting ARV needs up to 2010. Geneva: World Health Organization 2006. (Accessed 20 October 2009.) Available from http://www.who.int/hiv/ amds/ReportForecastingMeeting.pdf
6. Garren KW, S Rahim, Marsh K, Morris JB. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model. J Pharm Sci 2009. doi 10.1002/jps.21712 [Epub ahead of print].
7. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25:393-399. (Pubitemid 36638188)
8. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401-410. (Pubitemid 46555374)
9. Cawthorne P, Ford N, Limpananont J, Tienudom N, Purahong W. WHO must defend patients' interests, not industry. Lancet 2007; 369:974-975. (Pubitemid 46442740)
10. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir- containing regimens. J Acquir Immune Defic Syndr 2003; 33:594-600. (Pubitemid 36975846)
11. Autar RS, Boffito M, Hassink E, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56:908-913. (Pubitemid 41631916)